XORTX Therapeutics (XRTX) Return on Sales (2022 - 2023)
XORTX Therapeutics (XRTX) posted Return on Sales of 0.02% for Q4 2023, down 41.35% on a QoQ basis from 0.01% in Q3 2023, and down 1.0% year-over-year from 0.02% in Q4 2022.
XORTX Therapeutics (XRTX) Return on Sales (2022 - 2023) Analysis & Trends
XORTX Therapeutics' Return on Sales history runs 2 years deep, the most recent figure standing at 0.02% for Q4 2023.
- Quarterly Return on Sales fell 1.0% year-over-year to 0.02% in Q4 2023, while the trailing twelve-month figure through Dec 2023 was 0.02% (down 1.0% YoY) and the FY2022 annual result came in at 0.05%, changed N/A from the prior year.
- Return on Sales was 0.02% for Q4 2023 at XORTX Therapeutics, down from 0.01% in the prior quarter.
- Across five years, Return on Sales topped out at 0.01% in Q4 2022 and bottomed at 0.02% in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROS (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,801.52 Bn | 66,801.23 Bn | - | - |
| 2 | Nanobiotix | 1,916.61 Bn | 1,916.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.65 Bn | 466.85 Bn | 1.35 Bn | 0.00% |
| 5 | Vertex Pharmaceuticals | 121.94 Bn | 114.69 Bn | 2.59 Bn | 0.00% |
| 6 | Regeneron Pharmaceuticals | 69.85 Bn | 61.09 Bn | 3.31 Bn | 0.00% |
| 7 | Belite Bio | 63.06 Bn | 63.06 Bn | - | - |
| 8 | Argenx Se | 55.74 Bn | 50.56 Bn | 1.41 Bn | 0.00% |
| 9 | Revolution Medicines | 37.48 Bn | 37.48 Bn | - | - |
| 10 | XORTX Therapeutics | 2.91 Bn | 2.91 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -0.02% |
| Sep 30, 2023 | -0.01% |
| Jun 30, 2023 | -0.01% |
| Mar 31, 2023 | -0.01% |
| Dec 31, 2022 | -0.01% |
| Sep 30, 2022 | -0.01% |
| Jun 30, 2022 | -0.01% |
| Mar 31, 2022 | -0.01% |